虽然高达80％的霍奇金淋巴瘤（HL）患者可以通过一线治疗治愈，但复发/难治性HL仍然是一个重大的临床障碍，并且对于无法接受自体干细胞移植（ASCT）或治疗后复发的患者来说是致命的。近年来，已经研究了几种基于免疫的方法，旨在通过免疫系统对癌细胞的反应发挥可能的抗肿瘤作用。对新型药物进行的临床研究，包括布伦替单抗韦杜汀（BV）和PD-1抑制剂，在ASCT后复发病情中成功证明了它们的有效性。此外，研究组合策略的研究目标是减少复发和化疗相关毒性的风险，主要在未经治疗的早期不良或晚期经典HL中表现出鼓舞人心的结果（cHL）。其他未批准的免疫疗法，例如卡米丹鲁马单克隆抗体、双特异CD30 / CD16A抗体和CD30嵌合抗原受体（CAR）T细胞疗法是有希望的方法，它们可以增强患者可用的治疗手段。版权所有©2023 Elsevier B.V.保留所有权利。

Although up to 80 % of Hodgkin lymphoma (HL) patients are cured with first-line therapy, relapsed/refractory HL remains a major clinical obstacle and is fatal for patients who are not candidates for autologous stem cell transplantation (ASCT) or relapse after treatment. Several immune-based approaches have been investigated in recent years with the aim of exerting a possible antitumor effect through the immune system response to cancer cells. Clinical studies on novel agents, including brentuximab vedotin (BV) and PD-1 inhibitors, have successfully demonstrated their effectiveness in relapsed disease after ASCT. Additionally, studies examining combination strategies with the goal of reducing the risk of relapse and chemotherapy-related toxicity have showed encouraging results, mainly in untreated early unfavorable or advanced stage classical HL (cHL). Other non-approved immunotherapies such as camidanlumab tesirine, bispecific CD30/CD16A antibody, and CD30 chimeric antigen receptor (CAR) T-cell therapy are promising approaches that may reinforce the therapeutic arsenal available to patients.Copyright © 2023 Elsevier B.V. All rights reserved.